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ABSTRACT 
The goal of my study was to investigate the nocifensive behavioral and cellular effects of 
dihydroergotamine (DHE) and sumatriptan in a model of sustained trigeminal activation.  
Trigeminal nerves provide sensory innervation to the head and face and their activation 
has been implicated in migraine pathology.  The most commonly prescribed medications 
for migraine treatment are the triptan class of drugs.  However, triptans are not an 
effective therapy for all migraine patients and some develop triptan resistance.  Ergot-
derivatives, including DHE, could be a potential alternative for this subpopulation of 
patients. To cause activation of the trigeminal system, adult male Sprague Dawley rats 
were given an inflammatory injection of complete Freund’s adjuvant (CFA) or saline as a 
vehicle control in the temporomandibular joint capsule. Three and four days post-CFA-
injection, intraperitoneal injections of DHE, sumatriptan, or vehicle control were 
delivered.  I found that DHE, but not sumatriptan, was able to transiently inhibit CFA-
mediated increases in nocifensive withdrawal behavior.  Within the spinal cord, DHE was 
shown to inhibit CFA stimulated levels of the signaling protein PKA, which is known to 
promote central sensitization, and Iba1, a marker of activated microglial cells.  However, 
both DHE and sumatriptan were able to inhibit stimulated levels of GFAP, a protein used 
as a marker of activated astrocytes.   Results from my study provide evidence that DHE, 
but not sumatriptan, can inhibit nociception caused by prolonged activation of trigeminal 
neurons and the inhibitory effect is likely to involve suppressing development of central 
sensitization.  I propose that DHE may be therapeutically beneficial by blocking ongoing 
peripheral and central sensitization as characteristic of frequent episodic and chronic 
migraine. 
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1 
INTRODUCTION 
 
Pathology of Migraine 
 Migraine is characterized by a severe, debilitating headache that can be 
accompanied by somatic symptoms such as nausea, vomiting, sensitivity to light, sound, 
or odors, and visual disturbances known as auras. Migraine affects 16.6-22.7% of adults 
in the United States, occurring three times more often in females than males (Schwedt, 
2014).  Chronic migraine (defined as having a headache for 15 days a month for the 
previous three months) comprises 7.7% of all migraine cases and, as compared with 
episodic migraine, results in significantly more severe disability for the patient as well as 
a higher co-morbidity with depression and anxiety (Smitherman et al., 2013). Risk factors 
for episodic migraine progressing into chronic migraine include caffeine use, medication 
overuse, obesity, snoring or sleep apnea, psychiatric conditions, and stressful life events 
(Dodick, 2009). 
 Historically, migraine has been viewed as a vascular disease but research in the 
last few decades suggests that migraine has a strong neurological basis and it is now 
believed that sensitization and activation of the trigeminal nerve, the fifth cranial nerve, 
which provides sensory innervation of much of the head and face, underlies migraine 
pathology (Pietrobon and Moskowitz, 2013).  One proposed mechanism for this 
activation begins with cortical spreading depression (CSD), a period of enhanced 
neuronal activity that moves across the cortex, followed by a period of very low cortical 
neuronal activity (Xu et al., 2010).  The enhanced neuronal activity results in excessive 
extravasation of proteins and ions into the perivascular space that triggers vasodilation of 
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the meninges, including the middle meningeal artery (MMA), and subsequently causes 
excitation of trigeminal afferent neurons. Upon activation, these neurons release 
inflammatory neuropeptides like calcitonin gene-related peptide (CGRP) and substance P 
into the meninges as well as transmitting nociceptive signals centrally to the spinal 
trigeminal nucleus (STN).  Within the spinal cord, these neuropeptides activate 
parasympathetic pathways to release additional vasoactive and inflammatory molecules 
into the meninges, further increasing blood flow and sustaining neurogenic inflammation 
(Bolay et al., 2002). These events can lead to both peripheral and central sensitization, 
which are characterized by the lowering of the stimulus threshold required to elicit a 
neuronal response. Sensitization of nociceptive neurons disproportionately increases 
migraine pain (hyperalgesia), causes pain responses to normally non-painful stimuli 
(allodynia), and prolongs the migraine attack (Dodick and Silberstein, 2006). 
 
The Trigeminal System 
 The afferent sensory neurons of the trigeminal nerve are pseudounipolar with 
their cell bodies located in the trigeminal ganglion (TG). These neurons have peripheral 
processes that extend to the head and face and central processes that synapse with second 
order neurons in the spinal trigeminal nucleus (STN) of the upper spinal cord (Fig. 1).  
These fibers are either lightly myelinated Aδ fibers or unmyelinated C fibers that respond 
to thermal, mechanical, and chemical stimuli to relay nociceptive information to the 
central nervous system (CNS) (Devor, 1999, Rathee et al., 2002). These peripheral 
neurons are associated with several types of glial cells including Schwann cells, which 
provide the myelination that increases conduction speeds, as well as satellite glial cells, 
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which are found in close association with the neuronal cell bodies and help to modulate 
the excitability state of the trigeminal neurons (Thalakoti et al., 2007, Durham and 
Garrett, 2010b).  A single neuronal cell body is surrounded by several satellite glia, 
forming a functional unit that develops during the first few weeks of neonatal 
development (Hanani, 2005, Durham and Garrett, 2010a).  Importantly, increased 
paracrine and gap junction signaling between neurons and glia facilitates and maintains 
nociceptor sensitization and is thus implicated in the underlying pathology of migraine 
(Durham and Garrett, 2010b). 
 As the name implies, the TG has three branches that include the ophthalmic, the 
maxillary, and the mandibular (Lazarov, 2002) (Fig. 2). The ophthalmic branch (V1) 
contains only sensory neurons and serves many structures of the eye, the eyebrow and 
forehead region, and the upper sinuses (Shankland, 2001a). The maxillary branch (V2) is 
also only sensory in function and innervates all the structures surrounding the maxillary 
bone including the lower eyelid, skin of the midfacial region, the mucus membrane of the 
nasopharynx, the maxillary sinus, the soft palate and the roof of the mouth (Shankland, 
2001b). The mandibular branch (V3) is the largest of the three trigeminal nerve branches 
and contains both sensory fibers that innervate the lower jaw and motor fibers that 
innervate and control the muscles of mastication (Shankland, 2001c). 
 The STN receives fibers from all three branches of the TG and contains three 
subnuclei: the oralis, interpolaris, and caudalis (Bereiter et al., 2000).  The most inferior 
of these, the trigeminal nucleus caudalis (TNC) contains neurons involved in processing 
nociception from the head and face and is thus implicated in migraine pathology 
(Akerman et al., 2011). The second order neurons located in the outer laminas in the TNC 
4 
carry nociceptive signaling received from the TG and transmit it to the thalamus and 
cortex (Shankland, 2000). The TNC contains a large glial population, including 
astrocytes and microglia. In addition to rapid proliferation following injury, activated glia 
produce and release pro-inflammatory molecules that modulate the function and 
excitability of nearby neurons by changing the expression of ion channels and receptors 
within the plasma membrane (Guo et al., 2007).  Throughout the CNS, astrocytes form 
networks with each other connected by gap junctions, primarily formed by connexin 43, 
which allow the exchange of Ca
2+
 and other small molecules. Astrocytes have extensive 
contact with neuronal synapses as well as cerebral blood vessels, leading to a “tripartite 
synapse” theory which suggests that synapses are made up of pre- and post- synaptic 
neuronal processes as well as astrocytic processes, allowing the astrocyte network to 
modulate neuronal signals (Ji et al., 2013). Microglia, when activated, proliferate and 
migrate, undergoing morphological changes that allow them to become phagocytic 
(Ohsawa et al., 2004). 
 
Proteins Implicated in Inflammation 
 Migraine and other neuroinflammatory pathologies involving nociception are 
associated with an increased expression of mitogen activated protein (MAP) kinases, 
which activate signaling cascades in order to alter gene expression and release 
inflammatory mediators.  MAP kinase pathways are involved in a diverse range of cell 
functions, including differentiation, division, movement, and death, and are thus common 
research targets (Schaeffer and Weber, 1999).  Two of the most well studied groups of 
MAP kinases are extracellular signal-regulated kinase (ERK1/2) and p38.  These proteins 
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are activated via phosphorylation and then translocate to the nucleus where they activate 
transcription factors that directly regulate expression of inflammatory genes involved in 
production of cytokines, chemokines, and nitric oxide (Raman et al., 2007).  
 ERK is strongly activated by nerve growth factor (NGF), which maintains the 
nociceptor phenotype and also sensitizes nociceptors and ion channels (Nicol and Vasko, 
2007).  It has also been suggested that ERK plays an important role in neural plasticity, 
which can lead to tactile allodynia or movement-induced pain, both of which are 
important features of chronic pain (Ji et al., 2009).  ERK may also be involved in long 
term potentiation (Xin et al., 2006), an important feature of central sensitization (Ji et al., 
2003). 
 The signaling protein p38 is activated by cellular stress and proinflammatory 
cytokines (Ji et al., 2009). Once activated, p38 translocates to the nucleus and induces the 
phosphorylation of transcriptional factors that increase the biosynthesis of inflammatory 
mediators such as TNF-α and IL-1β (Ji and Woolf, 2001).  In addition, p38 can sensitize 
nociceptors posttranslationally, a much faster process than acting on gene expression (Jin 
and Gereau, 2006). 
 Another signaling cascade implicated in the production of inflammatory 
mediators involves activation of adenylyl cyclase-cAMP-protein kinase A (PKA) 
pathway by numerous inflammatory mediators including the prostaglandin E2 (PGE2) 
receptor, the adenosine receptor, and the serotonin (5-hydroxytryptamine or 5-HT) 
receptors (Taiwo and Levine, 1991).  PKA then modulates and enhances the tetrodotoxin-
resistant voltage-gated sodium currents that are found primarily in nociceptors, leading to 
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sensitization of those nociceptors (Aley and Levine, 1999) and hyperalgesia (Fitzgerald et 
al., 1999).   
 The class of P2X purinoceptors mediate vasoconstriction and contraction of 
visceral smooth muscle and are activated by α,β-methylene ATP (Burnstock, 2000). ATP 
functions in neuronal signaling by eliciting both fast- and slow-inactivating inward 
currents which depolarizes neurons (Xu and Huang, 2002). The subtype P2X3 is located 
in both sensory neurons and glia and is expressed in structures associated with pain signal 
processing, and thus has been implicated in cranial nociception, particularly through its 
association with Transient Receptor Potential V1 (TRPV1), which functions as a signal 
integrator downstream of several pro-inflammatory G-protein coupled receptors 
(Saloman et al., 2013).   
 The calcium binding adapter protein Iba1 is often utilized as a marker of activated 
microglia within the CNS and a marker of phagocytes within the PNS (Ohsawa et al., 
2004). Elevated levels of Iba1 are associated with inflammatory events such as increased 
proliferation and migration as well as an increase in the production and secretion of pro-
inflammatory cytokines and chemokines (Ito et al., 1998), all of which are required for 
repairing cellular damage (Kreutzberg, 1996).  Microglia are often described as 
macrophage-like as they rapidly proliferate and assume immune roles in both the central 
and peripheral nervous systems after injury (Ji et al., 2013) and have been shown to play 
a role in inflammatory pain (Zhou et al., 2008). 
 Glial fibrillary acidic protein (GFAP), an intermediate filament protein, is 
expressed in astrocytes, which are specialized glial cells that perform multiple functions 
within the central nervous system including formation of blood brain barrier and 
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modulating synaptic connections between neurons.  With respect to nociception, 
upregulation of GFAP expression correlates with the state of reactive astrogliosis, or the 
astrocyte’s response to injury and as such is used as a biomarker of these cells (Anderson 
et al., 2014).  Importantly, changes in GFAP are associated with morphological and 
biochemical events within astrocytes, which are found in close proximity to neurons and 
help to regulate the local extracellular environment and thus, the state of neuronal 
excitability. 
 
Migraine Therapies – Dihydroergotamine and Sumatriptan 
 Ergotamine has been used for the clinical treatment of migraine since the 1920’s, 
but its medicinal effects have been known and utilized since the middle ages (Hofmann, 
1978). The original source of ergot was the ascomycetous fungus Claviceps purpurea, an 
obligate pathogen that infects cultivated cereals, primarily rye.  When bread made from 
contaminated grains is consumed, the parasite can cause ergotism (also known as St. 
Anthony’s Fire), a neurological disease that can manifest as either convulsions and 
hallucinations or gangrene and necrosis of the extremities, depending on the strain of 
ergot contamination (De Costa, 2002).  However, its vasoconstrictive effects were often 
utilized by midwives to speed labor and manage post-partum hemorrhages. Ergot extract 
was first recommended for migraine treatment in 1868, when it was thought that migraine 
was due to hypersympathetic activity, and ergotamine was first isolated in 1918, followed 
by many clinical trials showing its efficacy throughout the 1920’s and ‘30’s (Tfelt-
Hansen and Koehler, 2008).  Ergotamine and its derivatives were then the standard anti-
migraine drug until the development of the triptan class of drugs in the 1990’s and even 
8 
after the advent of triptans, ergot derivatives may be chosen over a triptan due to their 
ability to lower the rate of headache recurrence (Tfelt-Hansen et al., 2000). 
 Dihydroergotamine (DHE) was synthesized in 1943 and, though originally meant 
as an anti-hypertensive agent, was first used to treat migraine in 1945.  DHE was shown 
to be effective for the treatment of both intermittent and intractable migraine in 1986, 
with less nausea and vomiting as well as fewer vasoconstrictor effects than ergotamine 
(Silberstein and McCrory, 2003).   
 Dihydroergotamine belongs to the tetracyclic ergoline family and differs from 
ergotamine by the hydrogen found at the 10 position on the tetracyclic ergoline ring (Fig. 
3) (Maurer and Frick, 1984).  DHE acts as an agonist upon multiple 5-HT (serotonin) 
receptor subtypes, α-adrenoreceptors, and dopamine receptors (Perrin, 1985, Cook et al., 
2009, Dahlof and Maassen Van Den Brink, 2012), with more receptors activated when it 
is administered via IV vs. an inhaled form (MAP0004). DHE has a much longer 
dissociation half-life from serotonin receptors than sumatriptan (Kori et al., 2012), 
possibly contributing the lower rate of headache recurrence seen with ergot derivatives.  
 Dihydroergotamine has been found to inhibit second-order trigeminocervical 
neurons in experiments with cats, similar to other proven anti-migraine agents including 
several triptans (Hoskin et al., 2004). DHE has also been found to inhibit central 
sensitization both when administered at the same time as a prolonged inflammatory 
stimulus as well as when administered 2.5 hours after the stimulus (Oshinsky et al., 
2012). This study contrasted DHE with zolmitriptan, which could not inhibit central 
sensitization in that model.  
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 Developed in the early 1990’s as a specific anti-migraine therapy, sumatriptan 
was the first of the triptan class of drugs designed to abort an episodic migraine attack.  It 
is a derivative of a non-ergot alkaloid, called an indole, and was initially developed as a 
selective constrictor of intracranial blood vessels (Moskowitz, 1993).  Sumatriptan shows 
a high specificity for 5-HT1 receptors, specifically the 5-HT1B and 5-HT1D, with a lower 
affinity for 5-HT1F receptors (Dahlof and Maassen Van Den Brink, 2012).  At 
concentrations above that found at clinically relevant doses, sumatriptan will display a 
weak affinity for 5-HT1A and 5-HT1E receptors.  Sumatriptan has no significant activity at 
other 5-HT receptor subtypes or at other non-5-HT receptor types such as adrenergic, 
dopaminergic, or histamine receptors.   
 Along with their vasoconstrictive effects, sumatriptan, DHE, and other 5-HT1 
agonists are thought to work through three possible pathways.  The first is through 
activation of the 5-HT1D receptors on trigeminal nerve terminals that innervate the 
meningeal blood vessels, blocking the release of inflammatory neuropeptides.  The 
second route is through activation of central 5-HT1B//1D//1F receptors in the trigeminal 
nuclear caudalis, which blocks transmission of nociception from first order to second 
order neurons. The third possible mode of action is via stimulation of 5-HT1B//1D 
receptors in the ventroposteromedial thalamus, preventing the processing of nociceptive 
input from second order to third order neurons within the thalamus.  (Dahlof and 
Hargreaves, 1998, Tepper et al., 2002, Dahlof and Maassen Van Den Brink, 2012). 
 
 
 
10 
Goals of Study  
 The goal of my study was to determine the effect of DHE in an animal model 
which mimics trigeminal system pathology associated with chronic migraine and to 
compare those effects to the effects of a well-known and widely accepted migraine 
treatment, sumatriptan.  I wanted to test the hypothesis that DHE, due to its less specific 
receptor-binding profile, would be more effective than sumatriptan in blocking 
nocifensive behaviors and then determine through immunohistochemistry which 
signaling pathways were most effected.  
 To test this hypothesis, I utilized behavioral and molecular techniques to 
investigate the effects of both of these drugs in an established model of chronic 
trigeminal nerve activation. Briefly, an inflammatory agent, complete Freund’s adjuvant 
(CFA) was injected into the temporomandibular joint capsule to cause sustained 
inflammation and activation of the trigeminal system, followed by an intraperitoneal 
injection of each of the drugs of interest and then both nocifensive behaviors and cellular 
changes were examined. Results from this study suggest that DHE is more effective than 
sumatriptan in blocking nocifensive responses and does so by uniquely attenuating 
cellular changes in nociceptive pathways. Based on my findings, I propose that DHE 
could be a useful alternative for those migraneurs dissatisfied or unresponsive to triptans. 
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Figure 1. Nociception pathway through the trigeminal system.  From the periphery, 
signals are transmitted up primary neurons to the STN in the spinal cord, where the 
primary neurons synapse with the secondary neurons.  From the STN, the signal is 
transmitted to the thalamus and then up tertiary neurons to the sensory cortex. 
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Figure 2. The trigeminal nerve. See text for details.  
(https://commons.wikimedia.org/wiki/File:Gray778.png#/media/File:Gray778.png) 
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Figure 3. Chemical structures of DHE (left) and sumatriptan (right). 
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MATERIALS AND METHODS 
 
Animals and Chronic Inflammation Model 
 All animal procedures in this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of Missouri State University (protocol # 
14-019.0A approved on 1/27/2014) in accordance with the guidelines established in the 
Animal Welfare Act and National Institutes of Health. Every effort was made to 
minimize animal suffering and to use the minimum number of animals. Adult male 
Sprague-Dawley rats (300–400 g; Charles River Laboratories, Wilmington, MA) were 
individually housed in clean plastic cages exposed to a 12-h light/dark cycle (light from 
7:00 a.m. to 7:00 p.m.) and allowed unrestricted access to food and water. 
 As a model to study prolonged trigeminal nerve activation as reported in frequent 
and chronic migraine, some rats received bilateral injections in the temporomandibular 
joint capsule of 50 µL complete Freund’s adjuvant (CFA; 1:1 CFA/saline; Sigma-
Aldrich, St. Louis, MO).  As a control, some rats were injected only with 50 µL of saline.  
Injections were administered using a 26½ G needle (Becton Dickinson, Franklin Lakes, 
NJ) attached to a 100 µL glass syringe (Hamilton Company, Reno, NV) while the 
animals were anaesthetized via inhalation of 3-5% isoflurane (Patterson Veterinary, 
Devens, MA). 
 Three days post-injection of CFA or saline, rats were given intraperitoneal (i.p.) 
injections of either dihydroergotamine [DHE; Tocris Bioscience, Bristol, UK; prepared at 
a concentration of 50 mg/mL in dimethyl sulfoxide (DMSO) and administered at a 
dosage of 10 mg/kg], an equivalent volume of the vehicle DMSO (Sigma-Aldrich), or 
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sumatriptan (brand name Alsuma; manufactured at a concentration of 6 mg/0.5 mL and 
administered at a dosage of 0.3 mg/kg; Pfizer, New York, NY).  See Table 1 for a 
summary of experimental conditions and number of animals utilized in my study.   
 Five days post-injection, animals were sacrificed via inhalation of CO2 followed 
by decapitation and tissues were collected for molecular analysis.  The animals used for 
behavioral testing were sacrificed in the same manner fourteen days post CFA injection.  
See Figure 6 for overall timeline of study.   
 
Nocifensive Responses to Mechanical Stimuli 
 For behavioral testing, animals were first acclimated to the Durham Animal 
Holder (Ugo Basile, Varese, Italy) (Fig. 4) for five minutes on three consecutive days 
then allowed two days to rest undisturbed before experimental readings were begun.  
Acclimation involved placing the animal in the holder and gently rubbing that rat’s face 
in the area to be tested with a plastic filament similar to the von Frey filaments so as to 
condition the animal to a mechanical stimulus.  This minimizes false reactions due to the 
animal being startled when measurements are taken at later timepoints during the 
experiment. 
 Nocifensive responses were determined using a series of calibrated von Frey 
filaments (60, 100, and 180 g; Ugo Basile) (Fig. 5) applied in increasing force to the 
cutaneous area directly over the TMJ. Base line readings were taken on the day prior to 
CFA or saline injections and further readings were taken two hours post-injection and 
days 3 (prior to i.p. injection), 5, 7, 10, and 14 post-injection.  Measurements were 
obtained between 8:00 and 10:00 a.m. (with the exception of the two hour post-injection 
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time-point).  The researcher responsible for the direct application of the filament was 
blinded to the experimental conditions.   
 Data are reported as the mean number of positive responses (a withdrawal of the 
animal’s head) out of five applications to each side of the face of 100 g force ± SEM.  
Statistical analysis was performed using a factorial ANOVA followed by Tukey’s post 
hoc with SPSS 21 software.  Differences were considered to be significant at p < 0.05. 
 
Tissue Collection, Preparation, and Immunostaining 
 Following sacrifice, the upper spinal cord and the trigeminal ganglia were 
removed. The spinal cord was trimmed at the obex and 5 mm posterior to the obex, 
allowing the area encompassing the spinomedullar junction (Vc/C1) transition zone, 
which contains the spinal trigeminal nucleus (STN), to be kept.  Tissues were placed in 
4% paraformaldehyde for fixation and incubated overnight at 4°C.  Tissues were then 
cryoprotected by placing them in a 15% sucrose solution and incubated for one hour at 
4°C before being moved to a 30% sucrose solution and incubated overnight at 4°C. 
 Tissues were quickly frozen in Optimal Cutting Temperature medium (OCT; 
Sakura Finetek, Torrance, CA) with the dorsal side (ganglia) or posterior side (spinal 
cord) facing up.  Fourteen micron longitudinal (ganglia) or transverse (spinal cord) 
sections were taken using a cryostat (Microm HM 525, Thermo Scientific, Waltham, 
MA) set at -24°C and sections were mounted on Superfrost Plus glass slides (Fisher 
Scientific, Pittsburgh, PA) then stored at -20°C until utilized for immunohistochemistry.  
Each slide contained one section of each experimental condition (Table 1) for that round. 
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 To minimize non-specific binding of antibodies and permeabilize the tissues, 
sections were incubated for twenty minutes in a solution of phosphate buffered saline (1X 
PBS; Sigma-Aldrich) that contained 5% donkey serum (Jackson ImmunoResearch, West 
Grove, PA) and 0.1% Triton-X (Fisher Scientific, Pittsburgh, PA).  Slides were rinsed 
with PBS and incubated with primary antibodies diluted in 5% donkey serum for either 
three hours at room temperature or overnight at 4°C in a humidity chamber constructed 
using a damp paper towel, parafilm, and a pipet tip box.  A summary of the antibody 
sources, dilutions, and incubation times is provided in Table 2.  Slides were then rinsed 
with 0.1% Tween 20 solution (Sigma-Aldrich) and incubated with appropriate secondary 
Alexa antibodies diluted in PBS for one hour at room temperature.  Slides were then 
rinsed with 0.1% Tween again, covered with Vectashield Mounting Media (H-1200) 
containing 4’6-diamidino-2-phenylin-dole (DAPI; Vector Laboratories, Burlingame, CA) 
to co-stain cell nuclei, and covered with a glass coverslip (Fisher Scientific, Pittsburgh, 
PA).  Slides were stored at 4°C prior to image collection. 
 
Microscopy and Image Analysis 
 Images (200x) of the medullary horn of the STN and the V3 region of the TG 
were collected using a Zeiss Axiocam mRm camera mounted on a Zeiss Imager Z1 
fluorescent microscope equipped with an ApoTome. Image acquisition and analysis was 
performed using Zeiss Zen Blue 2012 (Thornwood, NY).  All images within a set 
(meaning those images from sections on a single slide that are from the same round and 
immunostained with the same antibody) were balanced so that the non-staining, acellular 
regions of the STN or the fiber tracks of the TG appeared to be the same brightness.  The 
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images were then evaluated using a +/- system as follows: the control tissue was assigned 
a value of 0 and all other images within that set were compared to the level and number 
of cells positively stained and designated according to the following list:  
  0 = No change from control 
  + = Increased expression from control (approximately 50%) 
  ++ = Dramatically increased expression from control (approximately 100%) 
  - = Decreased expression from control (approximately 50%) 
  -- = Dramatically decreased expression from control (approximately 100%) 
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Table 1.  Experimental Conditions and Number of Animals Utilized in Study  
TMJ Injection i.p. Injection 
Behavioral 
n Number 
Molecular 
n Number 
Saline DMSO 6 2 
Saline DHE 6 2 
Saline Sumatriptan 6 2 
CFA DMSO 6 2 
CFA DHE 6 2 
CFA Sumatriptan 6 2 
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Table 2.  Summary of Antibodies and Incubation Conditions  
Antibody Company Product # Species Dilution Incubation 
PKA Epitomics 2113-1 Rabbit 1:500 3 hours, RT 
P-p38 Cell Signaling Technology 4511S Rabbit 1:200 Overnight, 4°C 
P-ERK Bioworld BS5016 Rabbit 1:200 Overnight, 4°C 
GFAP Abcam Ab53554 Goat 1:5000 3 hours, RT 
Iba1 Wako 019-19741 Rabbit 1:1000 3 hours, RT 
P2X3 ThermoScientific PA1-30936 Rabbit 1:500 Overnight, 4°C 
Alexa 488 Invitrogen A21206 Rabbit 1:200 1 hour, RT 
Alexa 568 Invitrogen A11057 Goat 1:200 1 hour, RT 
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Figure 4.  A Sprague Dawley rat in the Durham Animal Holder.  Slits were cut into the 
original holder to facilitate testing sensitivity of trigeminal neurons to a mechanical 
stimulus applied in the orofacial region of the rat.  The red color of the device prevents 
the animal from seeing the approach of the von Frey filaments and thus reduces non-
evoked withdrawal responses.  
22 
 
 
Figure 5. A 60 gram (left) and 100 gram (right) Von Frey filament.  These filaments were 
used to evoke a withdrawal response when applied to the orofacial region of the rat.  A 
positive withdrawal response was associated with bending of the filament. 
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Figure 6.  Experimental timeline.   * = CFA or saline injection in TMJ, # = i.p. treatment 
injection, XM = animals sacrificed for molecular studies, XB = animals from behavioral 
studies sacrificed, A = behavioral acclimations, BL = base line behavioral readings taken, 
underlined numbers = days on which further behavioral readings were taken (note that 
the day 3 readings were taken prior to administration of treatment injections). 
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RESULTS 
 
Effect of Dihydroergotamine and Sumatriptan on Nocifensive Response 
 Administration of DMSO, which served as a vehicle control for drug delivery, on 
days 3 and 4 post-saline injection did not elevate mean nocifensive responses above 2 out 
of 5 (Fig. 7).  Responses of animals that were injected with saline, which served as a 
vehicle control of CFA, and then administered sumatriptan did not differ significantly 
from those of the DMSO group at any timepoint.  In contrast, animals that received the 
saline injection and were then administered DHE did have significantly fewer nocifensive 
responses than the DMSO group on day 5 (p = 0.040), which corresponds to the 
timepoint on the day immediately following the DHE administration.  No further 
significant differences were found between experimental conditions at any later 
timepoints. 
 Following injection of CFA into the TMJ, nocifensive responses were 
significantly elevated as compared to the group that received saline injections (p = 0.005 
on day 5, p < 0.001 at all other timepoints after CFA injection) (Fig. 8).  Administration 
of sumatriptan on days 3 and 4 post CFA injection did not significantly affect nocifensive 
responses as compared to those that were administered DMSO at any timepoint.  
Administration of DHE on days 3 and 4 significantly lowered nocifensive responses on 
day 5 (p = 0.005) as compared to the DMSO group.  However, this effect was transient as 
no significant differences were seen for the remainder of the timepoints investigated.   
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Suppression of PKA Expression in the STN by Dihydroergotamine 
 All sections were examined using the nuclear stain DAPI, which fluorescently 
marks the nuclei of all cells. No differences in DAPI distribution were seen between any 
treatment conditions (data not shown). A representative image is shown in Figure 9, 
illustrating the overall cellular morphology as well as the area of interest to which all 
further STN images will be confined. 
 Within the control tissue, active PKA expression was localized in a narrow, 
somewhat diffuse band along the dorsal horn of the STN (Fig. 10). Injection of DHE 
following saline injection within the TMJ resulted in a much lighter and more diffuse 
band, suggesting a downregulation of basal PKA expression. Injection of sumatriptan 
following saline injection had no effect, with PKA staining pattern similar to that of 
control tissue. 
 Injection of CFA in the TMJ resulted in a robust increase in active PKA 
expression with a bright, discrete band along the medullary horn (outer laminas) 
surrounded by a wider band of bright and diffuse staining.  Injection of DHE following 
CFA injection greatly lowered PKA expression to below that of even control levels, with 
no discernable discrete band and only dim, diffuse staining along the horn.  In contrast, 
injection of sumatriptan following CFA injection resulted in a level of PKA expression 
that appears lower than that seen in the CFA and DMSO tissues, but is still more intense 
than the levels in control tissue. 
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P2X3 Expression is Repressed in the STN by Dihydroergotamine and Sumatriptan 
 Within the control tissue, P2X3 expression was limited to a diffuse band along the 
horn with sporadic brighter areas of intensity (Fig. 11). Treatment with DHE following 
saline injection in the TMJ diminishes those bright areas, leaving only a diffuse band of 
staining.  Treatment with sumatriptan following saline injection reduced the intensity of 
staining in the outer laminas as compared to control tissue. 
 Injection of CFA in the TMJ resulted in a very bright band of staining along the 
dorsal horn with numerous bright areas of staining. Treatment with DHE following the 
CFA injection brought the expression level down to near control levels, with a diffuse 
band of staining and sporadic bright areas. Treatment with sumatriptan following CFA 
injection inhibited the staining intensity, leaving only a diffuse band in the outer laminas. 
 
P-ERK Expression is Downregulated in the STN by Dihydroergotamine 
 Within the control tissue, there was little to no P-ERK staining visible, with only a 
few neurons expressing active levels of P-ERK (Fig. 12). Treatment with DHE or 
sumatriptan following saline injection did not change the staining appearance. 
 Injection of CFA in the TMJ resulted in a robust increase in the number of 
neuronal cells expressing elevated levels of P-ERK within the dorsal horn. Treatment 
with DHE following CFA injection reduced the number of P-ERK-positive neurons, but 
there was still a greater number than in the control tissues.  Treatment with sumatriptan 
following CFA injection appeared to have no effect on P-ERK expression as the staining 
pattern was similar to that seen in the CFA sample. 
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Repression of CFA-Stimulated Iba1 Expression in the STN by Dihydroergotamine  
 Within the control tissue, Iba1 expression, which is a biomarker of activated 
microglia, was faint, limited to a handful of glial cells along the dorsal horn (Fig. 13). 
Treatment with DHE following saline injection moderately increased Iba1 expression, as 
did treatment with sumatriptan following saline injection. 
 Injection of CFA in the TMJ greatly increased the number of activated microglial 
cells in the dorsal horn.  Treatment with DHE following CFA injection repressed Iba1 
levels down to near control levels. Treatment with sumatriptan following CFA injection 
somewhat reduced the number of activated glial cells as compared to the CFA sample, 
but to a lesser extent than did the DHE treatment. 
 
GFAP Expression is Inhibited in the STN by Dihydroergotamine and Sumatriptan 
 Within the control tissue, GFAP expression was observed in a sparse band of 
activated astrocytes within the dorsal horn (Fig. 14). Treatment with DHE following 
saline injection greatly reduced basal GFAP staining intensity and number of GFAP 
expression astrocytes, as did treatment with sumatriptan following saline injection. 
 Injection of CFA in the TMJ increased the number of active astrocytes, while 
treatment with DHE and sumatriptan both greatly reduced the intensity of staining to 
below control levels. 
 
Repression of P2X3 Expression in the TG by Dihydroergotamine and Sumatriptan  
 All sections were examined using the nuclear stain DAPI, which fluorescently 
marks the nuclei of all cells. No differences in DAPI distribution were seen between any 
28 
treatment conditions (data not shown). A representative image is shown in figure 15, 
illustrating the overall cellular morphology as well as the area of interest to which all 
further TG images will be confined. 
 Within the control tissue, there was very little P2X3 staining (Fig. 16A). Neither 
administration of DHE nor sumatriptan had an effect on the staining intensity. 
 CFA injection in the TMJ dramatically increased the amount of P2X3 staining, 
with numerous large- and small-diameter neurons showing fluorescent staining (Fig. 
16B).  Treatment with DHE and sumatriptan each reduced the amount of staining as 
compared to the CFA sample, but not to the low levels of the control tissue. 
 
Dihydroergotamine Inhibits CFA-Induced P-ERK Expression in the TG  
 There was very little P-ERK staining in the control tissue, mainly faint 
fluorescence in the cytoplasm of neurons (Fig. 17A). Treatment with DHE following 
saline injection had no effect on ERK expression.  Treatment with sumatriptan following 
saline injection, on the other hand, slightly upregulated ERK expression with some 
neurons showing ERK expression within the nucleus. 
 Following CFA injection, ERK expression was upregulated, with several neurons 
showing ERK expression within the nucleus (Fig. 17B). Treatment with DHE following 
CFA injection resulted in ERK expression similar to that of the control tissue. Treatment 
with sumatriptan following CFA injection had no effect on ERK expression, resulting in 
a staining pattern and intensity similar to that of the CFA sample. 
 
 
29 
Active p38 Expression is Downregulated in the TG by Dihydroergotamine 
 Within the control tissue, a small amount of neurons show P-p38 staining within 
the nucleus, a sign of activated P-p38 (Fig. 18A). Treatment with dihydroergotamine 
reduced this staining, with no visible neurons showing nuclear staining. Treatment with 
sumatriptan following saline injection resulted in a staining pattern similar to that seen in 
the control tissue. 
 Injection of CFA in the TMJ upregulated P-p38 expression, with the majority of 
neurons showing nuclear staining (Fig. 18B). Treatment with DHE and sumatriptan 
resulted in staining patterns similar to that seen in the control tissue, with only a few 
neurons showing nuclear staining. 
 
Iba1 Expression is Downregulated in the TG by Dihydroergotamine and 
Sumatriptan 
 Within the control tissue, a moderate number of glial cells brightly fluoresced 
(Fig. 19A). Treatment with DHE and sumatriptan each reduced the intensity of 
fluorescence in the glial cells. 
 Following CFA injection in the TMJ, more glial cells brightly fluoresced as 
compared to the control tissue (Fig. 19B). Administration of DHE following CFA 
injection greatly reduced the number of glial cells showing fluorescence as well as the 
intensity of fluorescence. Administration of sumatriptan following CFA injection slightly 
reduced the intensity of fluorescence, displaying a similar pattern and brightness to that 
of the samples administered sumatriptan following saline injection. 
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Figure 7. Effect of DHE and sumatriptan on basal responses. Treatment with DHE 
significantly inhibited nocifensive responses as compared to vehicle only on day 5.  
Values are reported as the average number of withdrawal responses to mechanical 
stimulation out of 5 applications to each side using a 100 g von Frey filament.  * p = 
0.040.   
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Figure 8. Effect of DHE and sumatriptan on nocifensive responses following CFA 
injection.  CFA mediated sustained and significant nocifensive responses beginning 2 
hours after injection and continuing for 14 days.  Treatment with DHE following CFA 
injection significantly inhibited nocifensive responses on day 5. Values are reported as 
the average number of withdrawal responses to mechanical stimulation out of 5 
applications to each side using a 100 g von Frey filament.  # p < 0.05. * p = 0.005. 
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Figure 9.  TNC morphology. A view of a full TNC slice stained with DAPI (top) and an 
enlarged view of the area of interest (bottom), which is outlined in white in the top image.  
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Figure 10. PKA expression in the STN.  DHE inhibits both basal levels of PKA 
expression as well as CFA-induced increases in PKA expression. Sumatriptan had no 
effect on basal PKA expression and only somewhat inhibited CFA-induced increases in 
PKA expression. Spinal cords were removed as described five days after saline or CFA 
injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 
and 4 post-saline/CFA injection.  Lower table displays changes in relative staining 
intensity (n = 2 independent experiments). 
34 
 
Figure 11. P2X3 expression in the STN. DHE and sumatriptan each inhibited basal P2X3 
expression. Sumatriptan inhibited CFA-induced increases in P2X3 expression to a greater 
extent than DHE. Spinal cords were removed as described five days after saline or CFA 
injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 
and 4 post-saline/CFA injection.  Lower table displays changes in relative staining 
intensity (n = 2 independent experiments). 
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Figure 12. P-ERK expression in the STN. Neither DHE nor sumatriptan had an effect on 
basal P-ERK expression. DHE somewhat inhibited CFA-induced increases in P-ERK 
expression while sumatriptan had no effect. Spinal cords were removed as described five 
days after saline or CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p. 
injections occurring on days 3 and 4 post-saline/CFA injection.  Lower table displays 
changes in relative staining intensity (n = 2 independent experiments). 
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Figure 13. Iba1 expression in the STN. DHE and sumatriptan treatment resulted in a 
slight increase in basal Iba1 expression. DHE greatly inhibited CFA-mediated Iba1 
increases while sumatriptan only somewhat inhibited CFA-mediated Iba1 increases. 
Spinal cords were removed as described five days after saline or CFA injection in the 
TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 and 4 post-
saline/CFA injection.  Lower table displays changes in relative staining intensity (n = 2 
independent experiments). 
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Figure 14. GFAP expression in the STN. DHE and sumatriptan each greatly inhibited 
both basal GFAP expression as well as CFA-mediated increases in GFAP expression. 
Spinal cords were removed as described five days after saline or CFA injection in the 
TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on days 3 and 4 post-
saline/CFA injection.  Lower table displays changes in relative staining intensity (n = 2 
independent experiments). 
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Figure 15. TG morphology. Full image of a TG slice stained with DAPI (top). Area 
outlined in white is enlarged in bottom left. Area outlined in white in bottom left image is 
enlarged in bottom right. 
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Figure 16. P2X3 expression in the TG. (A) Neither DHE nor sumatriptan had an effect on 
basal P2X3 expression in the TG. (B) DHE and sumatriptan each somewhat inhibited 
CFA-mediated increases in P2X3 expression in the TG. Ganglia were removed as 
described five days after saline or CFA injection in the TMJ with DMSO, DHE, or 
sumatriptan i.p. injections occurring on days 3 and 4 post-saline/CFA injection.  Lower 
table displays changes in relative staining intensity (n = 2 independent experiments). 
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Figure 17. P-ERK expression in the TG. (A) DHE had no effect on basal P-ERK 
expression while sumatriptan slightly upregulated basal P-ERK expression. (B) DHE 
inhibited CFA-mediated increases in P-ERK expression. Sumatriptan had no effect on 
CFA-mediated increases. Ganglia were removed as described five days after saline or 
CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p. injections occurring on 
days 3 and 4 post-saline/CFA injection.  Lower table displays changes in relative staining 
intensity (n = 2 independent experiments).
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Figure 18. Active p38 expression in the TG. (A) DHE greatly decreased basal P-p38 
expression while sumatriptan had no effect. (B) DHE and sumatriptan each inhibited 
CFA-mediated increases in P-p38 expression. Ganglia were removed as described five 
days after saline or CFA injection in the TMJ with DMSO, DHE, or sumatriptan i.p. 
injections occurring on days 3 and 4 post-saline/CFA injection. Lower tables display 
staining intensity as determined by previously described guidelines. 
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Figure 19. Iba1 expression in the TG. (A) DHE and sumatriptan each decreased basal 
Iba1 expression in the TG. (B) DHE greatly inhibited CFA-mediated increases in Iba1 
expression, while sumatriptan only somewhat decreased it. Ganglia were removed as 
described five days after saline or CFA injection in the TMJ with DMSO, DHE, or 
sumatriptan i.p. injections occurring on days 3 and 4 post-saline/CFA injection.  Lower 
table displays changes in relative staining intensity (n = 2 independent experiments). 
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DISCUSSION 
 
DHE Represses Nocifensive Responses to Mechanical Stimulation 
  The major finding from my study is that DHE, but not sumatriptan, was 
effective in blocking nociception associated with prolonged inflammation and sustained 
trigeminal neuron activation.  I hypothesized based on receptor binding profiles and a 
previous study in our laboratory (Masterson and Durham, 2010) that DHE may function 
by a different mechanism of action than sumatriptan, and therefore may be beneficial in 
decreasing nociception caused by persistent trigeminal nociceptor activation.  The 
differential ability of DHE and sumtriptan to modulate responses to mechanical 
stimulation likely lies in their different pharmacological profiles.  DHE predominantly 
acts as a pan-amine receptor agonist while sumatriptan binds selectively and with high 
affinity to the 5-HT1B and 5-HT1D receptors.  Similar to the triptans, DHE is known to 
bind to the serotonin 5-HT1B and 5-HT1D receptors (Goadsby, 2000, Cook et al., 2009).  
However, the potency of DHE binding to the different receptors depends on maximum 
plasma concentration (Cmax) achieved by the different routes of administration used for 
therapeutic purposes. When 1 mg of DHE is administered via IV, Cmax is about 45,289 
pg/mL, effective binding includes 8 serotonin receptors, 4 α-adrenoceptors, and 2 
dopamine receptors and, as a result, DHE IV treatment is associated with a number of 
unwanted side effects. When administered through oral inhalation (MAP0004, 6 
actuations, 1.8 mg per dose), the Cmax is about 5,241 pg/mL and effective bindings 
include only 4 serotonin receptors, 3 α-adrenoceptors, and 1 dopamine receptor and, as a 
result, some of the common side effects of the IV dosing were not reported.  My finding 
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that sumatriptan was not inhibitory in the CFA-induced trigeminal activation model was 
unexpected.  It should be noted that DHE only mediated a transient inhibitory effect on 
mechanical sensitivity of trigeminal primary neurons with a significant decrease in 
withdrawal responses on day 5 following DHE treatment on days 3 and 4.  On day 7, the 
average number of nocifensive responses was similar to that observed in the CFA alone 
treated animals.  Thus, it appears that a sustained inflammatory stimulus, as occurs in 
response to CFA injection into the TMJ capsule, results in a pathological condition of 
trigeminal activation that cannot be reversed by only two treatments of DHE.  Based on 
my results, I can only speculate that DHE would need to be administered on a daily basis 
to be an effective therapy for frequent episodic or chronic migraine.  
  My finding that sumatriptan could not inhibit ongoing peripheral and central 
sensitization of trigeminal nociceptive neurons differs from the results published by 
Burstein and Jakubowski (Burstein and Jakubowski, 2004).  In their experiment, the 
investigators used a rat model in which intracranial pain is used to induce cutaneous 
allodynia, a manifestation of central sensitization of the STN, to measure the effects of 
treatment with triptans given either before initiation of central sensitization or after it is 
established. Using this model, these researchers found that concomitant administration of 
sumatriptan and an inflammatory soup (IS), containing 1 mM histamine, serotonin, 
bradykinin, and 0.1 mM prostaglandin E2 in 10 mM HEPES buffer, pH 5.5, is applied to 
the dura mater effectively blocked the development of central sensitization. Specifically, 
experimental evidence included the lack of expansion of dural receptive fields or increase 
in dural indentation sensitivity, a lack of long-term spontaneous firing increases, and no 
increase in the magnitude of response to mechanical or thermal skin stimulation in central 
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trigeminovascular neurons.  Sumatriptan, administered after the establishment of central 
sensitization, reversed intracranial sensitivity of central trigeminovascular neurons, as 
evidenced by a reversal of IS-induced dural receptive field expansion and neuronal 
sensitivity to dural stimulation; however, it did not reverse the increased neuronal 
sensitivity to mechanical or thermal stimulation at the periorbital skin or the increased 
spontaneous firing. These findings suggest that the anti-nociceptive effects of triptans are 
mediated largely through pre-synaptic inhibition of transmitters release in the dorsal horn 
by the peripheral nociceptors, rather than post-synaptic inhibition of receptors on central 
trigeminovascular neurons (Oshinsky et al., 2012).  In another study using the same 
animal model, the effects of zolmitriptan and DHE were compared on the generation and 
maintenance of central sensitization. Zolmitriptan administered 1 hour before or 2.5 
hours after application of an IS to the dura mater did not inhibit central sensitization, as 
measured electrophysiologically, in the STN. In contrast, DHE given either before or at 
the time of IS application to the dura mater was able to block the induction of central 
sensitization.  When given after central sensitization of the TNC was established, DHE 
was able to reverse sensory thresholds to brush, pin, and pressure stimulation. These 
results suggest that DHE and triptans act by different mechanisms of action once central 
sensitization is established and that DHE, unlike a triptan, reverses central sensitization 
(Oshinsky et al., 2012).   The difference in the ability of DHE to reverse central 
sensitization is most likely due to the transient nature of the stimulus used in their study 
when compared to the persistent stimulus used in my model of trigeminal activation.   
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DHE Differentially Regulates Cellular Pathways 
 Results from my study provide evidence at the cellular level to help explain why 
administration of DHE on days 3 and 4 was sufficient to inhibit the nocifensive effect of 
CFA in response to mechanical stimulation.  DHE was found to inhibit the CFA-
stimulated increase in STN expression of PKA, P2X3, P-ERK, Iba1, and GFAP, which 
are all proteins implicated in the development and maintenance of central sensitization.  
In addition, DHE also repressed the stimulatory effect of CFA on P2X3, P-ERK, P-p38, 
and Iba1 in the trigeminal ganglion.  Each of these proteins is involved in modulating the 
excitability state of primary sensory trigeminal neurons.  For example, increased 
expression of the active phosphorylated form of the MAP kinase signaling protein ERK 
is associated with sensitization of primary and secondary nociceptive neurons that 
facilitates prolonged nociception (Dai et al., 2002, Ji, 2004).  Elevated levels of MAP 
kinases such as ERK and P38 promote and sustain neuronal sensitization by modulating 
the expression of receptors and ion channels, stimulating release of inflammatory 
molecules, and facilitating interactions with glial cells (Ji et al., 2009).  Similarly to our 
previous observations (Cady et al., 2014), I found that CFA injection in the TMJ 
increased the expression of Iba1, a protein used as a biomarker of activated macrophage 
cells (Nakamura et al., 2013), within the functional units of the ganglia.  Our finding of 
increased activation of macrophages in response to CFA-induced inflammation within the 
TMJ is in agreement with the results of previous studies involving trigeminal nerve 
activation caused by inflammatory stimuli (Villa et al., 2010, Franceschini et al., 2013). 
An increase in the activity level of macrophages within the ganglion is likely to facilitate 
the inflammatory response via the release of cytokines and other mediators and to 
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function as scavengers to remove cellular debris caused during pathology.  CFA also 
mediated an increase in Iba1 expression in microglia within the STN.  Activated 
microglial cells are known to increase the synthesis and release of pro-inflammatory 
mediators including cytokines and chemokines.   
 In agreement with results from our previous study (Cady et al., 2014), I found that 
CFA injection in the TMJ resulted in an upregulation of PKA expression within the STN.  
Elevated levels of PKA modulate nociceptive responses of primary neurons by enhancing 
sodium currents, sensitizing nociceptors. This pathway is activated by CGRP, which has 
been shown to be released in response to peripheral tissue injury (Seybold, 2009). Once 
CGRP binds to its receptor, which is located on neuronal cell bodies, astrocytes, and 
microglia, the concentration of the secondary messenger cAMP increases, resulting in 
activation of PKA. Activated PKA promotes and sustains central sensitization by 
phosphorylating proteins that regulate the excitability state of both neurons and glia.   I 
also observed an increase in the level of P2X3 expression in both the STN and TG.  P2X3 
receptors, which are abundantly expressed by TG neurons projecting to the dura (Durham 
and Garrett, 2010b) and upon activation by ATP are known to mediate acute and chronic 
pain (Durham and Russo, 2003, Olesen et al., 2004, Levy et al., 2005, Bowen et al., 2006, 
Bigal et al., 2007).   Similarly to my finding with DHE, results from another study using 
the selective P2X3 receptor antagonist A-317491 have provided evidence that blocking 
P2X3 receptors was effective in repressing nociception in inflammatory and neuropathic 
pain models (Vause et al., 2007).   This effect is not surprising since ATP activation of 
P2X3 receptors was shown to promote sensitization of primary afferent nociceptors 
involved in development of hyperalgesia (Cady et al., 2010).  Finally, I also observed an 
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increase in the expression of the structural protein GFAP, which is associated with 
activated astrocytes (Anderson et al., 2014).  The development and maintenance of 
peripheral and central sensitization of nociceptive neurons has been shown to be 
dependent on activated astrocytes (Watkins et al., 2001).    
 Although I found that all of these proteins were downregulated by DHE following 
CFA injection, the expression levels of many of them were also inhibited by sumatriptan.  
Only ERK and Iba1 were downregulated to a greater extent by DHE than by sumatriptan 
in both the ganglion and the spinal cord, while PKA was downregulated to a greater 
extent by DHE in the spinal cord.  Thus, I propose that decreased expression of these 
particular proteins are likely responsible for the inhibitory effect of DHE on nocifensive 
withdrawal responses following prolonged trigeminal activation.  In support of this 
notion, blocking ERK and PKA activation in nociceptive neurons and activation of 
microglia are associated with a decrease in the inflammatory response and promotes an 
anti-nocifensive state within animals (Aley and Levine, 1999, Watkins and Maier, 2002, 
Ji et al., 2009).   
 My results provide evidence that DHE induces cellular changes that are distinct 
from those induced by sumatriptan.  This observation is in agreement with previous 
results from our laboratory in which DHE, but not sumatriptan, repressed ATP-mediated 
sensitization of trigeminal ganglion neurons (Masterson and Durham, 2010).  In that 
study, neonatal rat trigeminal ganglia cultures were used to investigate effects of ATP, 
alpha, beta-methyl ATP (α,β-meATP), and DHE on intracellular calcium levels and 
calcitonin gene-related peptide (CGRP) secretion.  Pretreatment with ATP or α,β-meATP 
caused sensitization of neurons, via P2X3 receptors, such that a subthreshold amount of 
49 
potassium chloride (KCl) significantly increased intracellular calcium levels and CGRP 
secretion. Pretreatment with DHE repressed increases in calcium and CGRP secretion in 
response to ATP-KCl or α,β -meATP-KCl treatment.  Importantly, these inhibitory 
effects of DHE were blocked with an α2-adrenoceptor antagonist and unaffected by a 
5HT1B/D receptor antagonist. DHE also decreased neuronal membrane expression of the 
P2X3 receptor.  Results from that study provided evidence for a novel mechanism of 
action for DHE that involves blocking ATP mediated sensitization of trigeminal neurons, 
repressing stimulated CGRP release, and decreasing P2X3 membrane expression via 
activation of α2-adrenoceptors.  Further evidence that DHE may function differently 
from the triptans was provided by data showing that DHE treatment of trigeminal 
neurons did not change intracellular calcium levels as previously reported for the triptans. 
(Durham and Russo, 1999, 2003)  While DHE repression of potassium chloride–
stimulated release of CGRP from ATP-sensitized trigeminal neurons involved inhibition 
of intracellular calcium levels by decreasing membrane expression of the P2X3 receptor 
(Masterson and Durham, 2010), studies on sumatriptan demonstrated that its inhibitory 
effects were mediated via activation of 5-HT1 receptors. (Durham and Russo, 1999, 
2003). 
  
Summary and Future Directions 
 In summation, my study showed that DHE but not sumatriptan can transiently 
block nocifensive responses to mechanical stimulation following CFA-mediated chronic 
inflammation.  This is likely due to a different mechanism of action, as suggested by my 
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immunohistochemical results, which showed that DHE differentially regulates ERK, 
Iba1, and PKA. 
 Due to the transitory nature of its effects, DHE may be more helpful in treating 
frequent episodic migraine than chronic migraine, and thus prevent patients from 
progressing to chronic migraine. In fact, the best indicator of the likelihood of a patient 
developing chronic migraine is the frequency of their episodic migraines (Schwedt, 
2014).  Once a patient’s migraines become chronic, the only currently FDA-approved 
treatment is injection with Botox, so preventing that chronification should be a priority 
for sufferers of episodic migraine.  Currently, sumatriptan is the most commonly 
prescribed migraine treatment, but approximately 30% of patients do not get satisfactory 
results from it (Mathew, 2001).  My results suggest that since DHE works through 
different pathways than sumatriptan, it could be a good potential alternative for that 
subpopulation of patients.   Another advantage of DHE over the use of triptans is that 
DHE has been reported to cause minimal constriction of human cerebral arteries in 
vivo—significantly less than caused by triptans (Nilsson et al., 1999).   DHE did not have 
any vasoconstrictor effects on the porcine middle meningeal artery (Mehrotra et al., 
2006) but did cause vasoconstriction of the perfused middle cerebral artery of rats (Tfelt-
Hansen et al., 2007).  DHE was reported to increase resistance of the meningeal vascular 
bed in anesthetized cats (Lambert and Michalicek, 1996).   Evaluation of the effect of 
DHE in vitro on distal and proximal coronary arteries demonstrated no significant 
vasoconstriction (Labruijere et al., 2015).  Taken together, the results of human and 
animal studies show that DHE has variable and condition-dependent effects on cerebral 
and peripheral arteries and veins. As with other acute migraine therapies, there is no 
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direct evidence that vasoconstriction plays a primary role in the therapeutic effects of 
DHE. 
 In the future, it may be beneficial to look at several different iterations of the 
model presented in my study to determine the best efficacy of DHE.  Some possibilities 
include pre-treating with DHE prior to initiation of inflammation, continuing daily 
treatment throughout the course of the study, or increasing the doses of DHE and 
sumatriptan.  
Given the increasing prevalence and socio-economic impact of more frequent 
migraine attacks and the lack of effective medications to inhibit the progression from 
frequent to chronic migraine, more effective therapeutic approaches are in great need for 
this group of migraine sufferers.   Towards this end, a new method to deliver DHE in an 
aerosolized form that is rapidly absorbed by the lungs and minimizes unwanted side 
effects caused by oral or injectable administration of DHE is in development by the 
pharmaceutical company Allergan, and awaiting approval from the Food and Drug 
Administration.   
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